Navigating Virtual Tumor Boards for Prostate Cancer PSMA-PET Imaging

The panel shares their perspectives on the transition to virtual multidisciplinary tumor boards for patients with prostate cancer after the COVID-19 pandemic.

EP: 1.Risk Stratification of Patients with Prostate Cancer

EP: 2.Conventional Imaging for Prostate Cancer

EP: 3.Introduction to PSMA-Targeted PET Imaging

EP: 4.Approved PSMA-PET Imaging Tracer Options for Prostate Cancer

EP: 5.Practical Considerations for Selection of PSMA-PET Tracers

EP: 6.Impact of PSMA-Targeted Imaging Modalities on Management of Prostate Cancer

EP: 7.Overview of Available Clinical Guidelines on PSMA-PET Imaging in Prostate Cancer

EP: 8.Challenges of Implementing PSMA-Targeted PET Imaging in Prostate Cancer

EP: 9.Navigating and Overcoming Challenges of PSMA-PET Imaging Results Interpretation

EP: 10.Best Practices for Communication: A Multidisciplinary Perspective

Now Viewing

EP: 11.Navigating Virtual Tumor Boards for Prostate Cancer PSMA-PET Imaging

EP: 12.Unmet Needs in Imaging for Patients With Prostate Cancer

EP: 13.PSMA-Based Imaging and Theranostics: A Summary of Current Paradigm Shifts and a Look to the Future

EP: 14.Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate Cancer

Related Videos

Related Content

Advertisement

April 25th 2025

FDA clears AI-powered application for measuring prostate volume

Benjamin P. Saylor

Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

April 21st 2025

AUA 2025: What to watch for in urologic oncology

Benjamin P. Saylor Hannah Clarke

We preview several noteworthy P2 presentations in the urologic oncology space.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

April 15th 2025

Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC

Hannah Clarke

The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.

April 14th 2025

Study underway to assess 3-fraction SBRT regimen in prostate cancer

Hannah Clarke

"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.

Related Content

Advertisement

April 25th 2025

FDA clears AI-powered application for measuring prostate volume

Benjamin P. Saylor

Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

April 21st 2025

AUA 2025: What to watch for in urologic oncology

Benjamin P. Saylor Hannah Clarke

We preview several noteworthy P2 presentations in the urologic oncology space.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

April 15th 2025

Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC

Hannah Clarke

The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.

April 14th 2025

Study underway to assess 3-fraction SBRT regimen in prostate cancer

Hannah Clarke

"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.